Epcoritamab
Multispecific antibody
Also known as GEN3013
Evidence outlook
Approved: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (3)
- Relapsed or refractory large B-cell lymphoma (DLBCL, HGBCL, PMBCL, FL3B) after two or more lines of systemic therapy
- Monotherapy for adults with relapsed or refractory DLBCL after two or more lines of systemic therapy (conditional marketing authorisation, TEPKINLY)
- In combination with lenalidomide and rituximab for adults with relapsed/refractory grade 1, 2, or 3a follicular lymphoma (Notice of Compliance, reported 2026-09-24)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EPCORE DLBCL-1 NCT04628494 · Diffuse Large B-Cell Lymphoma Registry: NCT04628494 | 3 | Overall Survival (OS) (Up to approximately 4 years, 9 months) 2025-10-13 | Overall Survival (OS) (Up to approximately 4 years, 9 months): Epcoritamab 11.3 months (95% CI 7.8 to 15.7) | Investigator's Choice (IC) 10.3 months (95% CI 9 to 12.5) | not yet graded | link ↗ |
View 1 more trial
NCT05578976 NCT05578976 · Diffuse Large B-Cell Lymphoma Registry: NCT05578976 | 3 | Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5 (Up to Approximately 46 Months) 2027-06 | In progress: results expected 1 Jun 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (40)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other CD20 x CD3 drugs
Odronextamab, AZD5492, CND261, Plamotamab. Compare all 5 CD20 x CD3 drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Diffuse Large B-Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Epcoritamab: this drug | Approved | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Brentuximab Vedotin | Approved | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved | Monoclonal antibody | CD19 | Weak signal | NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants | |
| Acalabrutinib | Phase 3 | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Chidamide | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| Ibrutinib | Phase 3 | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 3 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Purinostat Mesylate | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-A1912 | Phase 3 | Antibody–drug conjugate | CD79b | not yet graded | No reviewed efficacy summary in this indication | |
| Zilovertamab Vedotin | Phase 2/3 | Antibody–drug conjugate | ROR1 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD5492 | Phase 1/2(overall) | Multispecific antibody | CD20 x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| CND261 | Phase 1(overall) | Biologic (subtype unspecified) | CD20 x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Plamotamab | Phase 1(overall) | Multispecific antibody | CD20 x CD3 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(55 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Epcoritamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (17)
February 2027 (1)
What to watch
March 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (2)
What to watch
What to watch
August 2027 (2)
September 2027 (3)
What to watch
What to watch
What to watch
October 2027 (3)
What to watch
What to watch
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (14)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
March 2028 (1)
What to watch
July 2028 (3)
What to watch
What to watch
What to watch
August 2028 (2)
What to watch
What to watch
September 2028 (1)
What to watch
October 2028 (3)
What to watch
What to watch
What to watch
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (8)
January 2029 (1)
What to watch
March 2029 (1)
May 2029 (1)
What to watch
June 2029 (1)
What to watch
October 2029 (1)
What to watch
December 2029 (3)
What to watch
What to watch
What to watch
2030 (8)
March 2030 (1)
What to watch
April 2030 (1)
What to watch
May 2030 (2)
June 2030 (1)
What to watch
October 2030 (2)
November 2030 (1)
What to watch
2031 (4)
January 2031 (1)
What to watch
May 2031 (1)
What to watch
September 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (1)
November 2032 (1)
What to watch
2037 (1)
November 2037 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent